

Kim Kramer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4217182/publications.pdf>

Version: 2024-02-01

65
papers

3,500
citations

201674

27
h-index

144013

57
g-index

67
all docs

67
docs citations

67
times ranked

4193
citing authors

#	ARTICLE	IF	CITATIONS
1	Next-generation sequencing of cerebrospinal fluid for clinical molecular diagnostics in pediatric, adolescent and young adult brain tumor patients. <i>Neuro-Oncology</i> , 2022, 24, 1763-1772.	1.2	37
2	Carboplatin During Craniospinal Radiotherapy for Children With Group 3 Medulloblastoma—A New Standard of Care?. <i>JAMA Oncology</i> , 2022, 8, 301.	7.1	0
3	Quantifying intraventricular drug delivery utilizing programmable ventriculoperitoneal shunts as the intraventricular access device. <i>Journal of Neuro-Oncology</i> , 2022, 157, 457-463.	2.9	1
4	IntraOmmaya compartmental radioimmunotherapy using ¹³¹ I-omburtamab—pharmacokinetic modeling to optimize therapeutic index. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 1166-1177.	6.4	9
5	Mast cell proliferation in the cerebrospinal fluid after intraventricular administration of anti-B7H3 immunotherapy. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 2411-2414.	4.2	1
6	EPCT-21. NEXT-GENERATION SEQUENCING OF CEREBROSPINAL FLUID FOR CLINICAL MOLECULAR DIAGNOSTICS IN ADOLESCENT AND YOUNG ADULT (AYA) BRAIN TUMOR PATIENTS. <i>Neuro-Oncology</i> , 2021, 23, i51-i51.	1.2	2
7	Phase I Trial of Oral Yeast-Derived β -Glucan to Enhance Anti-GD2 Immunotherapy of Resistant High-Risk Neuroblastoma. <i>Cancers</i> , 2021, 13, 6265.	3.7	6
8	Extracellular Vesicle and Particle Biomarkers Define Multiple Human Cancers. <i>Cell</i> , 2020, 182, 1044-1061.e18.	28.9	691
9	Response assessment in diffuse intrinsic pontine glioma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group. <i>Lancet Oncology</i> , The, 2020, 21, e330-e336.	10.7	59
10	Reduced-dose craniospinal irradiation for central nervous system relapsed neuroblastoma. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28364.	1.5	7
11	Assessing Cerebrospinal Fluid Flow Dynamics in Pediatric Patients with Central Nervous System Tumors Treated with Intraventricular Radioimmunotherapy. <i>Journal of Nuclear Medicine</i> , 2020, 61, 662-664.	5.0	3
12	Biodistribution and Dosimetry of Intraventricularly Administered ¹²⁴ I-Omburtamab in Patients with Metastatic Leptomeningeal Tumors. <i>Journal of Nuclear Medicine</i> , 2019, 60, 1794-1801.	5.0	29
13	Central nervous system neuroblastoma metastases pseudoprogression following intraventricular anti-B7-H3 radioimmunotherapy. <i>Journal of Neuro-Oncology</i> , 2019, 144, 227-229.	2.9	4
14	Targeted radioimmunotherapy for embryonal tumor with multilayered rosettes. <i>Journal of Neuro-Oncology</i> , 2019, 143, 101-106.	2.9	17
15	Treatment and outcome of adult-onset neuroblastoma. <i>International Journal of Cancer</i> , 2018, 143, 1249-1258.	5.1	23
16	A phase II study of radioimmunotherapy with intraventricular ¹³¹ I-m3F8 for medulloblastoma. <i>Pediatric Blood and Cancer</i> , 2018, 65, e26754.	1.5	46
17	Central nervous system relapse of rhabdomyosarcoma. <i>Pediatric Blood and Cancer</i> , 2018, 65, e26710.	1.5	27
18	Adoptive immunotherapy with haploidentical natural killer cells and Anti-GD2 monoclonal antibody m3F8 for resistant neuroblastoma: Results of a phase I study. <i>Oncoimmunology</i> , 2018, 7, e1461305.	4.6	49

#	ARTICLE	IF	CITATIONS
19	Convection-enhanced delivery for diffuse intrinsic pontine glioma: a single-centre, dose-escalation, phase 1 trial. <i>Lancet Oncology</i> , The, 2018, 19, 1040-1050.	10.7	201
20	A phase I study of perifosine with temsirolimus for recurrent pediatric solid tumors. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26409.	1.5	66
21	A phase I/IIb trial targeting the Pi3k/Akt pathway using perifosine: ^Long-term progression-free survival of patients with resistant neuroblastoma. <i>International Journal of Cancer</i> , 2017, 140, 480-484.	5.1	41
22	A phase I study of single-agent perifosine for recurrent or refractory pediatric CNS and solid tumors. <i>PLoS ONE</i> , 2017, 12, e0178593.	2.5	38
23	<i>MYCN</i>-amplified stage 2/3 neuroblastoma: excellent survival in the era of anti-GD2 immunotherapy. <i>Oncotarget</i> , 2017, 8, 95293-95302.	1.8	10
24	Arsenic Trioxide as a Radiation Sensitizer for ¹³¹I-Metaiodobenzylguanidine Therapy: Results of a Phase II Study. <i>Journal of Nuclear Medicine</i> , 2016, 57, 231-237.	5.0	17
25	Rare Primary Central Nervous System Tumors Encountered in Pediatrics. <i>Journal of Child Neurology</i> , 2016, 31, 1394-1398.	1.4	1
26	Lack of survival advantage with autologous stem-cell transplantation in high-risk neuroblastoma consolidated by anti-GD2 immunotherapy and isotretinoin. <i>Oncotarget</i> , 2016, 7, 4155-4166.	1.8	51
27	Low incidence of radionecrosis in children treated with conventional radiation therapy and intrathecal radioimmunotherapy. <i>Journal of Neuro-Oncology</i> , 2015, 123, 245-249.	2.9	22
28	Osteochondroma in long-term survivors of high-risk neuroblastoma. <i>Cancer</i> , 2015, 121, 2090-2096.	4.1	15
29	Prolonged progression-free survival after consolidating second or later remissions of neuroblastoma with Anti-G_{D2} immunotherapy and isotretinoin: a prospective Phase II study. <i>Oncolimmunology</i> , 2015, 4, e1016704.	4.6	52
30	Phase I Trial of a Bivalent Gangliosides Vaccine in Combination with \hat{I}^2 -Glucan for High-Risk Neuroblastoma in Second or Later Remission. <i>Clinical Cancer Research</i> , 2014, 20, 1375-1382.	7.0	118
31	Safety profile of long-term intraventricular access devices in pediatric patients receiving radioimmunotherapy for central nervous system malignancies. <i>Pediatric Blood and Cancer</i> , 2014, 61, 1590-1592.	1.5	29
32	Striking dichotomy in outcome of <i>MYCN</i>-amplified neuroblastoma in the contemporary era. <i>Cancer</i> , 2014, 120, 2050-2059.	4.1	36
33	Posterior reversible encephalopathy syndrome in neuroblastoma patients receiving anti-G_{D2} 3F8 monoclonal antibody. <i>Cancer</i> , 2013, 119, 2789-2795.	4.1	26
34	Radioimmunotherapy of Neuroblastoma. <i>Medical Radiology</i> , 2013, , 629-638.	0.1	0
35	Establishing successful cerebrospinal fluid flow for radioimmunotherapy. <i>Journal of Neurosurgery: Pediatrics</i> , 2012, 9, 316-319.	1.3	4
36	Murine Anti-GD2 Monoclonal Antibody 3F8 Combined With Granulocyte-Macrophage Colony-Stimulating Factor and 13-<i>Cis</i>-Retinoic Acid in High-Risk Patients With Stage 4 Neuroblastoma in First Remission. <i>Journal of Clinical Oncology</i> , 2012, 30, 3264-3270.	1.6	215

#	ARTICLE	IF	CITATIONS
37	Two-compartment model of radioimmunotherapy delivered through cerebrospinal fluid. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2011, 38, 334-342.	6.4	11
38	High-dose carboplatin-irinotecan-temozolomide: Treatment option for neuroblastoma resistant to topotecan. <i>Pediatric Blood and Cancer</i> , 2011, 56, 403-408.	1.5	21
39	Compartmental intrathecal radioimmunotherapy: results for treatment for metastatic CNS neuroblastoma. <i>Journal of Neuro-Oncology</i> , 2010, 97, 409-418.	2.9	208
40	Differential impact of high-dose cyclophosphamide, topotecan, and vincristine in clinical subsets of patients with chemoresistant neuroblastoma. <i>Cancer</i> , 2010, 116, 3054-3060.	4.1	36
41	Whole Neuraxis Irradiation to Address Central Nervous System Relapse in High-Risk Neuroblastoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 78, 849-854.	0.8	16
42	Reply to K. Satharasinghe et al. <i>Journal of Clinical Oncology</i> , 2009, 27, e235-e235.	1.6	2
43	A focal lesion in the falx cerebri: Harbinger of classic stage 4 neuroblastoma in an infant cured despite residual disease after minimal therapy. <i>Pediatric Blood and Cancer</i> , 2009, 53, 1340-1342.	1.5	2
44	Phase I Study of Targeted Radioimmunotherapy for Leptomeningeal Cancers Using Intra-Ommaya 131-I-3F8. <i>Journal of Clinical Oncology</i> , 2007, 25, 5465-5470.	1.6	121
45	Irinotecan Plus Temozolomide for Relapsed or Refractory Neuroblastoma. <i>Journal of Clinical Oncology</i> , 2006, 24, 5271-5276.	1.6	121
46	Five-day courses of irinotecan as palliative therapy for patients with neuroblastoma. <i>Cancer</i> , 2005, 103, 858-862.	4.1	26
47	Management of Neurologic Complications. , 2005, , 213-222.		1
48	Treatment of Neuroblastoma Meningeal Carcinomatosis with Intrathecal Application of 125 I-Emitting Atomic Nanogenerators Targeting Disialo-Ganglioside GD2. <i>Clinical Cancer Research</i> , 2004, 10, 6985-6992.	7.0	52
49	Favorable-Biology Neuroblastoma Presenting With Leptomeningeal Metastases?. <i>Journal of Pediatric Hematology/Oncology</i> , 2004, 26, 703-705.	0.6	4
50	Curability of Recurrent Disseminated Disease After Surgery Alone for Local-Regional Neuroblastoma Using Intensive Chemotherapy and Anti-GD2 Immunotherapy. <i>Journal of Pediatric Hematology/Oncology</i> , 2003, 25, 515-519.	0.6	21
51	Oral Topotecan for Refractory and Relapsed Neuroblastoma: A Retrospective Analysis. <i>Journal of Pediatric Hematology/Oncology</i> , 2003, 25, 601-605.	0.6	25
52	MONOCLONAL ANTIBODY-BASED THERAPY OF NEUROBLASTOMA. <i>Hematology/Oncology Clinics of North America</i> , 2001, 15, 853-864.	2.2	36
53	Extending Positron Emission Tomography Scan Utility to High-Risk Neuroblastoma: Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography as Sole Imaging Modality in Follow-Up of Patients. <i>Journal of Clinical Oncology</i> , 2001, 19, 3397-3405.	1.6	159
54	Phase II Trial of the Anti-GD2 Monoclonal Antibody 3F8 and Granulocyte-Macrophage Colony-Stimulating Factor for Neuroblastoma. <i>Journal of Clinical Oncology</i> , 2001, 19, 4189-4194.	1.6	192

#	ARTICLE	IF	CITATIONS
55	Antibody-based diagnostic and therapeutic innovations for human cancer. <i>Comprehensive Therapy</i> , 2001, 27, 183-194.	0.2	1
56	Neuroblastoma metastatic to the central nervous system. <i>Cancer</i> , 2001, 91, 1510-1519.	4.1	131
57	Disialoganglioside GD2 loss following monoclonal antibody therapy is rare in neuroblastoma. <i>Medical and Pediatric Oncology</i> , 2001, 36, 194-196.	1.0	33
58	N7: A novel multi-modality therapy of high risk neuroblastoma (NB) in children diagnosed over 1 year of age. <i>Medical and Pediatric Oncology</i> , 2001, 36, 227-230.	1.0	114
59	N7: A novel multi-modality therapy of high risk neuroblastoma (NB) in children diagnosed over 1 year of age. <i>Medical and Pediatric Oncology</i> , 2001, 36, 227-230.	1.0	1
60	Pilot study of topotecan and high-dose cyclophosphamide for resistant pediatric solid tumors. <i>Medical and Pediatric Oncology</i> , 2000, 35, 468-474.	1.0	64
61	Targeted radioimmunotherapy for leptomeningeal cancer using ¹³¹ I-3F8. <i>Medical and Pediatric Oncology</i> , 2000, 35, 716-718.	1.0	43
62	Oral Etoposide for Refractory and Relapsed Neuroblastoma. <i>Journal of Clinical Oncology</i> , 1999, 17, 3221-3225.	1.6	55
63	Detection of neuroblastoma in bone marrow by immunocytology: Is a single marrow aspirate adequate?. , 1999, 32, 84-87.		12
64	Synovial sarcoma mimicking desmoplastic small round-cell tumor: Critical role for molecular diagnosis. , 1999, 32, 97-101.		21
65	Pharmacokinetics and acute toxicology of intraventricular ¹³¹ I-monoclonal antibody targeting disialoganglioside in non-human primates. <i>Journal of Neuro-Oncology</i> , 1997, 35, 101-112.	2.9	18